Design Therapeutics is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTAC molecules. The U.S. Food and Drug Administration has granted Fast Track designation to Co.'s primary Friedreich ataxia (FA) GeneTAC development candidate (DT-216) for the treatment of patients with FA. Co.'s second GeneTAC development candidate (DT-168) is an eye drop for the treatment of Fuchs Endothelial Corneal Dystrophy. Co.'s third program based on the GeneTAC platform is myotonic dystrophy type-1. Co. continues to develop its GeneTAC portfolio in preclinical studies to address other serious nucleotide repeat expansion-driven monogenic diseases. The DSGN stock yearly return is shown above.
The yearly return on the DSGN stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the DSGN annual return calculation with any dividends reinvested as applicable (on ex-dates).
|